SCHEMBL5345894

SCHEMBL5345894

O=C(Nc1cnc(Cl)nc1)c1cccc(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 7/20 1.00
KCNQ2 O43526 7/20 1.00
KCNQ5 Q9NR82 6/20 1.00
KCNE1 P15382 5/20 1.00
KCNQ1 P51787 5/20 1.00
KCNK3 O14649 2/20 0.63
KCNK9 Q9NPC2 2/20 0.63
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
ALDH1A1 P00352 2/20 0.62
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
GRM5 P41594 1/20 0.59
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086307 0.85 KCNQ3 (1.00) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL5346150 0.85 KCNQ3 (1.00) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL14516639 0.83 KCNQ3 (0.71) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL23406057 0.83 KCNQ3 (0.71) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL29743886 0.83 KCNQ3 (0.71) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL3675463 0.82 KCNK3 (0.84) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL5338598 0.81 KCNQ3 (1.00) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL3786882 0.80 KCNK3 (0.87) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL14516646 0.80 KCNQ3 (0.71) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1
SCHEMBL3674558 0.80 KCNK3 (0.71) KCNQ3KCNQ2KCNQ5KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205307-B2 Pyrimidines as novel openers of potassium ion channels ICAGEN, INC. (US) 2007-04-17 US disclosed
US-7205307-B2 Pyrimidines as novel openers of potassium ion channels ICAGEN, INC. (US) 2007-04-17 US disclosed
US-7205307-B2 Pyrimidines as novel openers of potassium ion channels ICAGEN, INC. (US) 2007-04-17 US disclosed
EP-1483259-A4 PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS ICAGEN INC (US) 2005-12-14 EP disclosed
EP-1483259-A1 PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS Icagen, Inc. (US) 2004-12-08 EP disclosed
US-20030181465-A1 Pyrimidines as novel openers of potassium ion channels ICAGEN, INC. 2003-09-25 US disclosed
WO-2003068767-A1 PYRIMIDINES AS NOVEL OPENERS OF POTASSIUM ION CHANNELS ICAGEN, INC. (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181465-A1 Pyrimidines as novel openers of potassium ion channels KCNJ1, KCNJ2, KCNJ11 KCNQ3 22/4885KCNQ2 12/4885KCNQ5 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.